Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upacicalcet (PLS240) in Secondary Hyperparathyroidism with ESKD on Hemodialysis
NCT05836220Phase 3Completed
- Sponsor
- Pathalys Pharma
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of upacicalcet in secondary hyperparathyroidism (SHPT) (3 arms), sponsored by Pathalys Pharma. Primary endpoints: Proportion of participants with a >=30% decrease in mean iPTH at Week 27, Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dL and 3 more. Started May 2023; status: completed.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT05836220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836220.